biopharmaceutical; covid-19 vaccines; business model
Abstract :
[en] The 2020 COVID-19 pandemic undermines the world economy, the affordability and accessibility of our health systems. It puts an increasing strain on global production, supply and value chains. The research and development of a set of COVID-19 vaccines is an unprecedented triumph of rapid innovation. The sense of urgency has prompted academic research institutions, big pharmaceuticals and dedicated biotechnology companies to develop vaccines targeting the SARS-CoV-2 coronavirus disease. Simultaneously, it unlocks new value for business, patients and society. Consequently, new business models have come to the forefront.
Disciplines :
Strategy & innovation
Author, co-author :
Segers, Jean-Pierre ; Université de Liège - ULiège > HEC Liège : UER > UER Finance et Droit: Diagnostic et contrôle de l'entreprise
Language :
English
Title :
Big pharma’s search for a COVID-19 vaccine: Take It To The Limit !
Publication date :
12 August 2021
Journal title :
Journal of Innovation Management
eISSN :
2183-0606
Publisher :
Universidade do Porto, Faculdade de Engenharia (FEUP), Portugal
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Chesbrough, H. (2020). To recover faster from Covid-19, open up: Managerial implications from an open innovation perspective. Industrial Marketing Management, 88, 410-413.
Debruyne, L. (2021). The global challenge of vaccine access: the CEPI initiative. I3H-virtual webinar.
Garret, L. (1995). The Coming Plague: Newly Emerging Diseases in a World Out of Balance. Penguin Books.
Geneva Network (2021). A joint declaration on the importance of IPRs to Covid vaccine manufacturing scale-up and future pandemic preparedness. Accessed July 2021: https://geneva-network.com/ research/a-joint-declaration-on-the-importance-of-iprs-to-covid-vaccine-manufacturing-scale-up-and-future-pandemic-preparedness/
Leclerc, O., Smith, J. (2018). How new biomolecular platforms and digital technologies are changing R&D. McKinsey. Accessed July 2021: https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/ our-insights/how-new-biomolecular-platforms-and-digital-technologies-are-changing-r-and-d?cid= eml-web
Mention, A-L., Pinto Ferreira, J.J., Torkkeli, M. (2020). Coronavirus: a catalyst for change and innovation, Journal of Innovation Management, 8 (1), 1-5.
Pharma.be (2020). The Belgian Biopharmaceutical Sector: a vibrant and leading biopharmaceutical valley in Europe. Accessed July 2021: https://pharma.be/fr/component/library/library/ 335-new-brochure-the-belgian-biopharmaceutical-sector-a-vibrant-and-leading-biopharmaceutical-valley-in-europe. html?Itemid=
Sahin, U., Karikó, K., Türeci, Ö. (2014). mRNA-based therapeutics - developing a new class of drugs. Nat Rev Drug Discov 13, 759-780. https://doi.org/10.1038/nrd4278
Segers, J.P. (2017a), The interplay of regional systems of innovation, strategic alliances and open innovation. The Case of New Biotechnology Firms in the bioRegions of Flanders & Wallonia (Belgium). Doctoral dissertation. Liège: Université de Liège - Atelier des Presses. http://hdl.handle.net/2268/207369
Segers, J.P. (2017b). Dr. Jean-Pierre Segers Explores Regional Innovation Systems in Belgian Pharmaceutical Industry. Accessed July 2021: https://blog.uiin.org/2017/11/dr-jean-pierre-segers-explores-regional-innovation-systems-belgian-pharmaceutical-industry/. Amsterdam: UIIN.
Segers, J.P., Gaile-Sarkane, E. (2020). From Creative Destruction to Creative Disruption: Lessons for Selected and Strategic Industries. Proceedings of The 24th World Multi-Conference on Systemics, Cybernetics and Informatics: Innovation and Technology Transfer in Emerging Economies.
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., Mayhew, S. (2020). The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery, 19, 305-306. https://doi.org/10.1038/d41573-020-00073-5
Vanhaverbeke, W. (2021). There is a better solution than waiving Covid virus vaccine patents. Accessed July 2021: https://www.linkedin.com/pulse/better-solution-than-waiving-covid-virus-vaccine-wim-vanhaverbeke/ ?trackingId=j%2Fgux91%2FT8C4Tn8FXUl7FQ%3D%3D
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
